title: Torticollis in mice intravenously infected with Mycobacterium tuberculosis.
abstract: Female BALB/cAnNCrl (n = 170; age, 6 to 9 wk) mice were infected by intravenous inoculation of 5 × 10(6) cfu Mycobacterium tuberculosis strain Erdman (ATCC 35801). Between day 52 and 5 mo after infection, 10 of the 170 mice infected according to this protocol developed torticollis, including mice in treatment groups that received combination antibiotic therapy of rifampin-pyrazinamide or moxifloxacin-rifampin-pyrazinamide. Torticollis did not develop in mice receiving isoniazid- rifampin-pyrazinamide therapy, nor was it present in the cohort of aerogenically infected mice. Affected mice were euthanized, and complete necropsy evaluation was performed on 4 mice. Gross necropsy evaluation revealed typical tuberculosis lesions in lungs of infected mice. Histologic evaluation of tissues revealed granulomatous otitis media with intralesional acid-fast bacilli consistent with Mycobacterium tuberculosis. These cases represent an unusual finding specific to the intravenous mouse model of Mycobacterium tuberculosis and may represent a model of a similar condition in humans that is known as tuberculous otitis media.
authors: Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
authors: Elizabeth R
authors: ER
authors: Magden
authors: Cristina M
authors: CM
authors: Weiner
authors: Janet C
authors: JC
authors: Gilliland
authors: Mary Ann
authors: MA
authors: DeGroote
authors: Anne J
authors: AJ
authors: Lenaerts
authors: Lon V
authors: LV
authors: Kendall
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects; D001344:Autopsy / Q000662:veterinary; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004432:Ear, Middle / Q000382:microbiology / Q000473:pathology; D005260:Female; D024841:Fluoroquinolones; D007275:Injections, Intravenous; D007538:Isoniazid / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000502:physiology*; D010033:Otitis Media / Q000209:etiology* / Q000382:microbiology / Q000473:pathology; D011718:Pyrazinamide / Q000008:administration & dosage / Q000009:adverse effects; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects; D014103:Torticollis / Q000209:etiology* / Q000382:microbiology / Q000473:pathology; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D011718:Pyrazinamide; D000077266:Moxifloxacin; D007538:Isoniazid; D012293:Rifampin